JPRN-UMIN000032725已完成未知
A prospective Single-center Study of Pharmacokinetics and Pharmacogenetics of Regorafenib in Patients with Metastatic Colorectal Cancer - Study of Pharmacokinetics and Pharmacogenetics of Regorafenib
Cancer Institute Hospital of Japanese Foundation for Cancer Research0 个研究点目标入组 30 人开始时间: 2018年5月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria are mainly as follows (regardless of gender): 1. Has synchronous multiple primary cancer within 5 years (except for carcinoma in situ ) 2.Taking CYP3A4 inhibitors or inducers(eg, phenytoin, carbamazepine, rifampin, phenobarbital, ketoconazole, macrolide antibiotics). 3. Has complication as follows a) poorly controlled diabetes b) uncontrolled hypertensions c) cirrhosis, liver failure, renal insufficiency d) intestinal paralysis, ileus e) interstitial lung disease, pulmonary fibrosis, emphysema f) active infection g) cardiac disease h) cerebrovascular disorder, brain metastasis i) hemorrhagic ulcer J) psychiatric disorder 4. Is a pregnant or lactating female 5. Amalgamation of mental disease or psychotic manifestation 6. The investigator considers not suitable for the study
研究者
相似试验
进行中（未招募）
1 期
A Multi-center Study to Evaluate How CCP-020 (Diacerein 1% ointment) is Absorbed in the Blood and Removed from the Body in Patients with Epidermolysis Bullosa (EB)EUCTR2018-000439-29-NLCastle Creek Pharmaceuticals, LLC20
进行中（未招募）
1 期
A Multi-center Study to Evaluate How CCP-020 (Diacerein 1% ointment) is Absorbed in the Blood and Removed from the Body in Patients with Epidermolysis Bullosa (EB)EUCTR2018-000439-29-GBCastle Creek Pharmaceuticals, LLC4
撤回
不适用
A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein after Maximum Use, Topical Administration of CCP-020 (Diacerein 1% ointment) to Patients with Epidermolysis Bullosa (EB)Epidermolysis BullosaNL-OMON46073Castle Creek Pharmaceuticals, LLC8
进行中（未招募）
不适用
An Open Single-centre Study on the Pharmacokinetics and Pharmacodynamics of Esomeprazole After Once Daily Oral Administration for 7 Days in Preterm Infants and NeonatesGastraesdophageal Reflux DiseaseMedDRA version: 14.1Level: LLTClassification code 10018203Term: GERDSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2012-001160-29-Outside-EU/EEAAstraZeneca AB38
未知
1 期
A Single Dose Study to Evaluate the Pharmacokinetics and Glucodynamics of insulin peglispro (LY2605541) in Healthy Male Japanese SubjectsJPRN-jRCT2080222319Eli Lilly Japan K.K.